<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

descriptionPublicationkeyboard_double_arrow_right Article 03 Mar 2022 Belgium, Italy Publisher:Massachusetts Medical SocietyJournal:New England Journal of Medicine, volume 386, pages 892-894 (issn: 0028-4793, eissn: 1533-4406,

Authors: Domachowske J; Madhi SA; Simões EAF; Atanasova V; Cabañas F; Furuno K; Garcia-Garcia ML; +12 Authors

doi: 10.1056/nejmc2112186

handle: 2078.1/262477 , 11568/1184451

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

- Summary
- Subjects
- Metrics

Abstract

The efficacy and safety of nirsevimab in the treatment of medically attended respiratory syncytial virus (RSV) infections of the lower respiratory tract in otherwise healthy, late preterm and term infants were assessed in the phase 2B1 and phase 3 MELODY2 trials. An ongoing phase 2–3 trial (ClinicalTrials.gov number, NCT03959488. opens in new tab) is evaluating the safety and pharmacokinetics of nirsevimab in infants at risk for severe RSV infection of the lower respiratory tract who are eligible to receive palivizumab. [...]

Countries

Belgium, Italy

Related Organizations

University of Pisa
Italy
Hôpital Femme-Mère-Enfant
France
University of the Witwatersrand
South Africa
Shenyang Aerospace University
China (People's Republic of)
AstraZeneca (United Kingdom)
United Kingdom

View all View all

Keywords

Lung Diseases, Nirsevimab, Prematurity, respiratory syncytial virus (RSV) infections;, Heart Diseases, Infant, Newborn, Infant, Infant, Premature, Diseases, Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Antiviral Agents, Injections, Intramuscular, Chronic Disease, Humans, Infant, Premature, Palivizumab

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	97
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%